Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.0452W HIGH $4.46
Volume
7.98 M
Value Traded
11.07 M
Short % Float
23.12%
-6.67%Week
-19.08%1 Month
-30%3 Month
-48.53%6 Month
-92.55%5 Year
-90.91%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
483.69 M
EPS (TTM)
-0.48
P/E Ratio
-
Ent. Value
60.10 M
Total Shares
345.36 M
Float Shares
257.83 M
Insiders
25.37%
Institutions
71.17%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ALLO Catalyst Timeline
Dated clinical, regulatory and corporate events for Allogene Therapeutics, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Allogene Therapeutics, Inc.
242Total events
16Upcoming
46Tier-1 (high impact)
2018 to 2029Coverage
Upcoming catalysts 2
Event history 50
▲Interim Analysiscemacabtagene ansegedleucelTrial
Interim futility analysis data cutoff
1L Large B-cell Lymphoma (LBCL)source ↗
▲Enrollment Milestonecemacabtagene ansegedleucelTrial
Achieved 2026 goal of activating more than 80 sites
1L Large B-cell Lymphoma (LBCL)source ↗
▲RMATcemacabtagene ansegedleucelDesignation
FDA granted RMAT designation for cema-cel as first-line consolidation therapy for LBCL
large B-cell lymphoma (LBCL)source ↗
▲Fast Track Designationcemacabtagene ansegedleucelDesignation
FDA granted Fast Track designation to cema-cel for ALPHA3 development program
large B-cell lymphoma (LBCL)source ↗
▲Interim Analysiscemacabtagene ansegedleucelTrial
Interim futility analysis from ALPHA3 trial reported MRD clearance and ctDNA data
large B-cell lymphoma (LBCL)source ↗
▲Biomarker Datacemacabtagene ansegedleucelClinical Data
Plasma ctDNA decreased by 97.7% at Day 45 in cema-cel arm vs 26.6% increase in observation arm
large B-cell lymphoma (LBCL)source ↗
▲Safety Data Updatecemacabtagene ansegedleucelClinical Data
Cema-cel well-tolerated with no treatment-related serious adverse events, no CRS, ICANS, GvHD, or high-grade infections
large B-cell lymphoma (LBCL)source ↗
▲Full ResultsALLO-316Clinical Data
Phase 1 results of ALLO-316 published in Journal of Clinical Oncology
advanced or metastatic renal cell carcinoma (RCC)source ↗
▲RMATcemacabtagene ansegedleucelDesignation
FDA granted RMAT designation for cema-cel
1L Large B-cell Lymphoma (LBCL)source ↗
▲Fast Track Designationcemacabtagene ansegedleucelDesignation
FDA granted Fast Track designation for cema-cel
1L Large B-cell Lymphoma (LBCL)source ↗
▲Interim Analysiscemacabtagene ansegedleucelTrial
Interim futility analysis supports cema-cel potential
1L Large B-cell Lymphoma (LBCL)source ↗
◆Topline ReadoutALLO-329Clinical Data
Initial data from first dosing cohort of RESOLUTION trial for ALLO-329
autoimmune diseases (SLE, lupus nephritis, scleroderma, inflammatory myositis)source ↗
◆Enrollment Milestonecemacabtagene ansegedleucelTrial
Lymphodepletion selection and futility analysis shifted to 1H 2026
Large B-Cell Lymphomasource ↗
●Oral PresentationPresentation
Major Symposium: Off-the-Shelf Cell Therapies for Cancer and Beyond by David Chang
▲IND Clearancecemacabtagene ansegedleucelIND
Regulatory clearance in South Korea and Australia to expand ALPHA3 trial
large B-cell lymphomasource ↗
▲Interim Analysiscemacabtagene ansegedleucelTrial
Interim futility analysis results from first 24 patients announced
large B-cell lymphomasource ↗
●Poster PresentationCD70Presentation
Poster: Preclinical Evaluation of Allogeneic BCMA/CD70 Dual CAR T Cells for High-Risk Multiple Myeloma
High-Risk Multiple Myelomasource ↗
▲PublicationALLO-329Presentation
Nature Communications publication of pre-clinical data for ALLO-329
autoimmune diseasessource ↗
▲Trial InitiationALLO-329Trial
Phase 1 RESOLUTION dose escalation rheumatology basket trial actively enrolling
autoimmune diseases (SLE, scleroderma, inflammatory myositis)source ↗
▼Equity OfferingCorporate
Pricing of underwritten public offering of 87,500,000 shares at $2.00 per share for gross proceeds of $175 million
▲Interim Analysiscemacabtagene ansegedleucelTrial
Interim futility analysis showed 58.3% MRD clearance in cema-cel arm vs 16.7% in observation arm
first-line consolidation large B-cell lymphoma (LBCL)source ↗
●Oral Presentationcemacabtagene ansegedleucelPresentation
Conference call and webcast to discuss interim futility analysis
first-line consolidation large B-cell lymphoma (LBCL)source ↗
◆Interim Analysiscemacabtagene ansegedleucelTrial
Interim futility analysis of ALPHA3 trial comparing MRD clearance rates between cema-cel and observation
large B-cell lymphoma (LBCL)source ↗
◆Enrollment Updatecemacabtagene ansegedleucelTrial
Patient screening and enrollment expected to begin in Q2 2026 in South Korea and Australia
large B-cell lymphomasource ↗
▲Interim Analysiscemacabtagene ansegedleucelTrial
Planned interim futility analysis from ALPHA3 trial reported
Large B-cell Lymphomasource ↗
●Quarterly UpdateCorporate
Fourth quarter and full year 2025 financial results and business update
▲Milestone PaymentCorporate
Return of $23.7 million in escrow funds from Servier arbitration outcome
◆Biomarker DataALLO-329Clinical Data
First clinical update with biomarker data and clinical proof-of-concept data
Autoimmune diseases (SLE, myopathies, systemic sclerosis)source ↗
●Trial Initiationcemacabtagene ansegedleucelTrial
Additional sites in Australia and South Korea expected to open
Large B-cell Lymphoma (LBCL)source ↗
◆Enrollment Completecemacabtagene ansegedleucelTrial
Enrollment completion expected
Large B-Cell Lymphomasource ↗
◆Topline Readoutcemacabtagene ansegedleucelClinical Data
IDSMB interim EFS analysis expected in 1H 2026
Large B Cell Lymphomasource ↗
▲Enrollment CompleteALLO-316Trial
Phase 1b cohort of TRAVERSE trial completed enrollment
renal cell carcinoma (RCC)source ↗
▲IP Litigation RulingIP / Competition
Favorable arbitration outcome for Servier vs Cellectis regarding cema-cel rights
◆Poster Presentationcemacabtagene ansegedleucelPresentation
Trial-in-Progress poster presentation of ALPHA3 at ASH 2025
large B-cell lymphoma (LBCL)source ↗
◆Preclinical PoCALLO-329Preclinical
Proof-of-concept data expected by YE 2025
Autoimmune Diseasesource ↗
▲Enrollment CompleteALLO-316Trial
Phase 1b cohort enrollment completed in TRAVERSE trial
Renal Cell Carcinomasource ↗
▲Trial InitiationALLO-329Trial
Phase 1 RESOLUTION trial dose escalation ongoing
Autoimmune diseasesource ↗
▲Enrollment CompleteALLO-316Trial
Enrollment completed in Phase 1b cohort at DL2
Renal Cell Carcinomasource ↗
▲FDA Feedback ReceivedALLO-316FDA Meeting
Aligned with FDA on pivotal trial design
Renal Cell Carcinomasource ↗
Past FDA Catalysts and PDUFA Decisions
How ALLO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | ALLO-329 (CD19/CD70) | Phase 1 data readout | Phase 1 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C43 / 100
Pipeline Score
$376M
Pipeline Value
Fair Value
Valuation Signal
6
Drugs Scored
0.7x
rNPV / MCap
Top 30%
Micro Cap(rank 198 of 658)
Percentile Rank
Allogene Therapeutics, Inc. carries a moderate pipeline score (43/100), with $940M risk-adjusted pipeline value, led by ALLO-715 in Relapsed/Refractory Multiple Myeloma (Phase 1), across $51B in total addressable markets.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALLO-715 Gene therapyCompletedNCT04093596 | Relapsed/Refractory Multiple Myeloma | Phase 1 | COMPLETED | 73 | Jan 27, 2025 |
Clinical Trial Results
Readouts, endpoints and source filings for every ALLO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ALLO-316 Fast TrackRMAT | metastatic renal cell carcinoma | Phase 1 | 2026-07-15 | confirmed response rate: 31%; responses range: 8 to 18+ months; median overall survival: not yet reached; patients enrolled: 51; patients treated: 46; median follow up time: 28.8 months; phase 1b patients: 22; high cd70 tps patients: 16Read More | Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid TumorsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Douglas Earl MartinOfficer (SVP, General Counsel) | Sell | -29,697 488,267 held | $2.12 | 08/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALLO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 1 % (400 %) | 46.69 M | 22.45 M | 491.22% ( 18.65 M) |
ALLO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALLO ranks across every disease it competes in
Competitive Position is a premium feature
See how ALLO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALLO News
ALLOAllogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
Allogene Therapeutics has announced the retirement of Geoffrey Parker, its Chief Financial Officer, effective November 6, 2026. Parker will continue to lead the finance team until his retirement while the company searches for a successor. Both Parker and CEO Zachary Roberts acknowledged his significant contributions during a critical phase for the company.
Read more →ALLOAllogene Therapeutics Announces Participation in September Investor Conference
Allogene Therapeutics announced its participation in the Citi Biopharma Back to School Conference on September 9, 2026. The company focuses on developing allogeneic CAR T products for cancer and autoimmune diseases. Webcasts of the event will be available on their website, providing updates on their innovative therapies.
Read more →ALLOAllogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Allogene Therapeutics reported strong progress in its clinical trials for Cema-Cel and ALLO-329. The Phase 2 ALPHA3 trial for Cema-Cel in LBCL has shown promising interim results, leading to FDA designations that could expedite its development. The company also reported a solid financial position with $423.6 million in cash as of June 30, 2026.
Read more →ALLOAllogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
Allogene Therapeutics will report its second quarter 2026 financial results on August 12, 2026, followed by a conference call and webcast. The company focuses on developing allogeneic CAR T products for cancer and autoimmune diseases. The event will provide insights into their business progress and future plans.
Read more →ALLO▲ +9%on this news
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
Allogene Therapeutics has received FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations for cemacabtagene ansegedleucel (Cema-Cel) as a first-line consolidation therapy for large B-cell lymphoma. The designations were based on promising results from the ALPHA3 trial, which demonstrated substantial minimal residual disease (MRD) clearance. The therapy was well-tolerated, with no treatment-related hospitalizations reported.
Read more →ALLOAllogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
Allogene Therapeutics announced promising Phase 1 results for ALLO-316, a CAR T therapy targeting CD70 in metastatic renal cell carcinoma. The study demonstrated a 31% confirmed response rate, with all responders remaining progression-free at analysis. The safety profile was manageable, supporting further clinical development. The findings highlight the potential of ALLO-316 as a treatment option for advanced RCC.
Read more →ALLOAllogene Therapeutics Announces Planned CEO Succession
Allogene Therapeutics announced a leadership transition as Dr. David Chang steps down as CEO after eight years, effective June 30, 2026. Zachary Roberts, currently EVP and CMO, will succeed him starting July 1, 2026. The Board praised Chang's contributions and expressed confidence in Roberts' ability to drive innovation in allogeneic CAR T therapies.
Read more →ALLOMay 26, 2026 3:30 PM EDT : TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
The article discusses the TD Cowen 7th Annual Oncology Innovation Summit, scheduled for May 26, 2026. It highlights the event's focus on insights related to the ASCO and EHA conferences. The post appears to be a brief announcement without detailed content or analysis.
Read more →ALLO▲ +6%on this newsshared move
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
Read more →ALLOAllogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
Allogene Therapeutics reported positive interim results from its Phase 2 ALPHA3 trial, indicating that 58.3% of patients treated with Cema-Cel achieved minimal residual disease (MRD) clearance. The company also highlighted a favorable safety profile and significant cash reserves following a public offering. The ongoing Phase 1 RESOLUTION trial for ALLO-329 is showing early signs of clinical activity.
Read more →ALLO▲ +6.5%on this news
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
Allogene Therapeutics will report its first quarter 2026 financial results and provide a business update on May 13, 2026. A live audio webcast and conference call will follow the announcement. The company focuses on developing allogeneic CAR T products for cancer and autoimmune diseases, aiming for reliable and scalable therapies.
Read more →ALLOAllogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
Allogene Therapeutics has received regulatory approval to expand its pivotal Phase 2 ALPHA3 trial to South Korea and Australia. This trial evaluates cemacabtagene ansegedleucel (cema-cel) for patients with large B-cell lymphoma. The expansion aims to enhance patient enrollment and leverage established clinical research infrastructures in these countries. Initial results indicate cema-cel's effectiveness in clearing minimal residual disease.
Read more →ALLOAllogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
Allogene Therapeutics announced its participation in the AACR Annual Meeting 2026, showcasing advancements in allogeneic CAR T therapies. The presentations emphasize the potential of these therapies to enhance patient access and simplify treatment delivery. The company is also exploring applications in autoimmune diseases, aiming to provide off-the-shelf solutions for various conditions.
Read more →ALLOAllogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
Allogene Therapeutics has successfully closed a public offering of 87.5 million shares at $2.00 each, raising $200.4 million. The funds will be used for general corporate purposes, including clinical trial and research expenses. The offering was managed by several financial institutions, indicating strong market interest.
Read more →ALLOAllogene Therapeutics Announces Pricing of Public Offering of Common Stock
Allogene Therapeutics announced the pricing of a public offering of 87.5 million shares at $2.00 each, aiming to raise $175 million. The offering is set to close around April 16, 2026, pending customary conditions. Proceeds will support various corporate needs, including clinical trials and R&D. The company has granted underwriters a 30-day option for additional shares.
Read more →ALLOAllogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
Allogene Therapeutics announced the publication of pre-clinical data for ALLO-329, a dual-targeted CAR T therapy for autoimmune diseases. The study highlights the potential of ALLO-329 to effectively target CD19+ B cells and CD70+ T cells, enhancing CAR T cell persistence and reducing the need for lymphodepletion. The Phase 1 RESOLUTION trial is currently enrolling patients, with initial data expected in June 2026.
Read more →ALLO▼ -25.5%on this newsshared move
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
Allogene Therapeutics announced a proposed public offering of $175 million in common stock, with an option for underwriters to purchase an additional $26.25 million. The proceeds will be used for general corporate purposes, including clinical trial and R&D expenses. The offering is subject to market conditions and is facilitated by major financial institutions.
Read more →ALLO▲ +12.5%on this newsshared move
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
Allogene Therapeutics has reported positive interim results from its pivotal ALPHA3 trial, showing that 58.3% of patients treated with cemacabtagene ansegedleucel (Cema-Cel) achieved minimal residual disease (MRD) negativity, compared to 16.7% in the observation arm. The treatment demonstrated a rapid reduction in plasma ctDNA levels and was well-tolerated with no serious adverse events. Enrollment for the trial is expected to complete by the end of 2027, with further analyses planned.
Read more →ALLO▼ -6.5%on this news· ran to -25% by day 3shared move
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
Allogene Therapeutics will announce the interim futility analysis data from its pivotal Phase 2 ALPHA3 trial involving cemacabtagene ansegedleucel (Cema-Cel) for first-line consolidation in large B-cell lymphoma. The conference call and webcast are scheduled for April 13, 2026, at 5:30 a.m. PT. This analysis is a significant step in evaluating the therapy's effectiveness.
Read more →About Allogene Therapeutics, Inc.
Headquarters210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
Founded2017
BIOPHARMAWATCH ELITE PLUS
Trade the next ALLO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime